Yuhui Li

Dr. Yuhui Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
YZYunzhi Zhufeng
Yunzhi Zhufeng
JXJun Xu
Jun Xu
MMMiao Miao
Miao Miao
YWYifan Wang
Yifan Wang
YLYimin Li
Yimin Li
JHJing He
Jing He
The microbiota has been observed altered in autoimmune diseases, including idiopathic inflammatory myopathies (IIMs), and associated with different treatments. Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. In this study, 13 patients with active IIMs were enrolled and received 1 ×106 IU of IL-2 subcutaneously every other day for 12 weeks plus standard care. The clinical response and immune response were assessed. Stool samples were obtained to explore the structural and functional alterations of the fecal microbiota targeting the V3–V4 region of the 16S rRNA gene and analyze their associations with clinical and immunological characteristics. Our study demonstrated that diversity of microbiota decreased remarkably in patients with IIMs, compared to healthy controls. The inflammatory-related bacteria, such as Prevotellaceae increased, while some butyrate-producing bacteria, such as Pseudobutyrivibrio, Lachnospiraceae, Roseburia, and Blautia, decreased significantly. The alteration associated with disease activities in patients with IIMs. After low-dose IL-2 treatment, 92.31% (12/13) of patients achieved IMACS DOI at week 12. Proportion of Treg cells significantly increased at week 12 compared with that in baseline (15.9% [7.73, 19.4%] vs. 9.89% [6.02, 11.8%], P = 0.015). Interestingly, certain butyrate-producing bacteria increase significantly after IL-2 treatment, like Lachnospiraceae, Pseudobutyrivibrio, etc., and are associated with a rise in L-Asparagine and L-Leucine. The effects of low-dose IL-2 on gut microbiota were more apparent in NOD mice. Together, the data presented demonstrated that low-dose IL-2 was effective in active IIMs and highlighted the potential for modifying the intestinal microbiomes of dysbiosis to treat IIMs.

9 May 2024 in Energy
Verified
Journal Article
Closed access
YLYuhui Li
Yuhui Li
YHYinmin Huang
Yinmin Huang
HChanyu chen
hanyu chen
FWFeng Wei
Feng Wei
Zunhua ZhangZunhua Zhang
Zunhua Zhang
MZMengni Zhou
Mengni Zhou

26 December 2020 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
YLYimin Li
Yimin Li
XJXiaohui Jia
Xiaohui Jia
XSXiaolin Sun
Xiaolin Sun
LSLianjie Shi
Lianjie Shi
FLFuan Lin
Fuan Lin
JHJing He
Jing He

15 July 2021 in Chinese Medical Journal
Verified
Journal Article
Open access
YCYukchiu Chung
Yukchiu Chung
ZLZhi-Chang Li
Zhi-Chang Li
XSXiao-Lin Sun
Xiao-Lin Sun
YLYan-Ying Liu
Yan-Ying Liu
MSMiao Shao
Miao Shao
XZXue-Wu Zhang
Xue-Wu Zhang
Background: Psoriatic arthritis (PsA) is an inflammatory arthropathy characterized by psoriasis and bone erosion on radiology. Dickkopf-1 (Dkk-1) is considered to be the main inhibitor of the Wnt signaling pathway and results in reduced osteoblast proliferation. The aim of this study was to investigate the serum level of Dkk-1 and its association with bone erosion in PsA patients. Methods: Serum Dkk-1 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 69 patients with PsA and 60 controls, including 39 rheumatoid arthritis (RA) patients, and 21 healthy controls (HCs). Rheumatoid factor and anti-cyclic citrullinated peptide levels were also determined by ELISA. The association of Dkk-1 level with clinical and laboratory features of PsA was analyzed. Logistic regression analysis was used to analyze the risk factors for bone erosion in PsA. Results: Dkk-1 was elevated in 68.1% (47/69) of the patients with PsA, 46.2% (18/39) of RA patients, and 9.5% (2/21) of HCs. Serum Dkk-1 concentration was significantly higher in PsA patients compared with that in HCs. The level of serum Dkk-1 was correlated with a swollen joint count, and levels of complement components 3 and 4. Elevated Dkk-1 level (odds ratio = 4.440, 95% confidence interval: 1.246–15.817, P = 0.021) was identified as the risk factor for bone erosion in PsA. Conclusions: The serum level of Dkk-1 is abnormally elevated in PsA patients. The elevation of Dkk-1 might be involved in the mechanism of bone erosion in patients with PsA.

16 August 2023 in Clinical Immunology
Verified
Journal Article
Closed access
YLYimin Li
Yimin Li
JXJun Xu
Jun Xu
YHYixiang Hong
Yixiang Hong
ZLZijun Li
Zijun Li
XXXiaoyan Xing
Xiaoyan Xing
XSXiaolin Sun
Xiaolin Sun

25 February 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
YLYimin Li
Yimin Li
YLYuhui Li
Yuhui Li
YWYuguang Wang
Yuguang Wang
LSLianjie Shi
Lianjie Shi
FLFuan Lin
Fuan Lin
XSXiaolin Sun
Xiaolin Sun
Full Papers; Authors: Y. Li, Y. Li, Y. Wang, L. Shi, F. Lin, Z. Zhang, J. Zhang, F. Xu, X. Sun